IL133216A0 - 2-ä4-[4(4,5-Dichloro-2-methylimidazol-1-yl) butyl]-1 piperazinylü-5-fluoropyrimidine preparation and therapeutic use - Google Patents
2-ä4-[4(4,5-Dichloro-2-methylimidazol-1-yl) butyl]-1 piperazinylü-5-fluoropyrimidine preparation and therapeutic useInfo
- Publication number
- IL133216A0 IL133216A0 IL13321698A IL13321698A IL133216A0 IL 133216 A0 IL133216 A0 IL 133216A0 IL 13321698 A IL13321698 A IL 13321698A IL 13321698 A IL13321698 A IL 13321698A IL 133216 A0 IL133216 A0 IL 133216A0
- Authority
- IL
- Israel
- Prior art keywords
- methylimidazol
- fluoropyrimidine
- dichloro
- butyl
- piperazinylü
- Prior art date
Links
- -1 4,5-Dichloro-2-methylimidazol-1-yl Chemical group 0.000 title 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- GHLXRTOLSFXWOA-UHFFFAOYSA-N 2-[4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]piperazin-1-yl]-5-fluoropyrimidine Chemical compound CC1=NC(Cl)=C(Cl)N1CCCCN1CCN(C=2N=CC(F)=CN=2)CC1 GHLXRTOLSFXWOA-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000037175 Travel-Related Illness Diseases 0.000 abstract 1
- 208000012886 Vertigo Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000027119 gastric acid secretion Effects 0.000 abstract 1
- 201000003152 motion sickness Diseases 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 231100000889 vertigo Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9706738A FR2763950B1 (fr) | 1997-06-02 | 1997-06-02 | 2- {4- [4-(4,5-dichloro-2-methylimidazol-1-yl)butyl] -1- piperazinyl }-5-fluoropyrimidine, sa preparation et son utilisation therapeutique |
| PCT/EP1998/003190 WO1998055476A1 (fr) | 1997-06-02 | 1998-05-28 | 2-{4-[4-(4,5-dichloro-2- methylimidazol-1-yl)butyl] -1-piperazinyl}-5-fluoropyrimidine, sa preparation et son utilisation therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL133216A0 true IL133216A0 (en) | 2001-03-19 |
Family
ID=9507480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13321698A IL133216A0 (en) | 1997-06-02 | 1998-05-28 | 2-ä4-[4(4,5-Dichloro-2-methylimidazol-1-yl) butyl]-1 piperazinylü-5-fluoropyrimidine preparation and therapeutic use |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6303608B1 (pl) |
| EP (1) | EP1007522B1 (pl) |
| JP (1) | JP4344890B2 (pl) |
| KR (1) | KR100556559B1 (pl) |
| CN (1) | CN1094491C (pl) |
| AT (1) | ATE228126T1 (pl) |
| AU (1) | AU732722B2 (pl) |
| BR (1) | BR9810240A (pl) |
| CA (1) | CA2292746A1 (pl) |
| DE (1) | DE69809564T2 (pl) |
| DK (1) | DK1007522T3 (pl) |
| ES (1) | ES2149691B1 (pl) |
| FR (1) | FR2763950B1 (pl) |
| HU (1) | HUP0002905A3 (pl) |
| IL (1) | IL133216A0 (pl) |
| NO (1) | NO318757B1 (pl) |
| NZ (1) | NZ501566A (pl) |
| PL (1) | PL190777B1 (pl) |
| PT (1) | PT1007522E (pl) |
| RU (1) | RU2191184C2 (pl) |
| TR (1) | TR199903001T2 (pl) |
| WO (1) | WO1998055476A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101152658B1 (ko) * | 2009-04-30 | 2012-06-18 | 한국과학기술연구원 | 세로토닌 5-ｈｔ6 길항 활성 효과를 갖는 피페라진 화합물 함유 조성물 |
| RU2660583C1 (ru) * | 2017-08-15 | 2018-07-06 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Применение буспирона для лечения функционального головокружения |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2642759B1 (fr) | 1989-02-09 | 1991-05-17 | Laboratorios Esteve Sa | Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante |
| FR2672052B1 (fr) | 1991-01-28 | 1995-05-24 | Esteve Labor Dr | Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments. |
| FR2665161B1 (fr) * | 1990-07-26 | 1992-11-27 | Esteve Labor Dr | Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments. |
| FR2673628B1 (fr) * | 1991-03-07 | 1993-07-09 | Esteve Labor Dr | Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles. |
| FR2712808B1 (fr) | 1993-11-25 | 1996-02-16 | Esteve Labor Dr | Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique . |
| FR2742052B1 (fr) * | 1995-12-12 | 1998-04-10 | Esteve Labor Dr | Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports |
-
1997
- 1997-06-02 FR FR9706738A patent/FR2763950B1/fr not_active Expired - Fee Related
-
1998
- 1998-05-28 WO PCT/EP1998/003190 patent/WO1998055476A1/fr not_active Ceased
- 1998-05-28 KR KR1019997011267A patent/KR100556559B1/ko not_active Expired - Fee Related
- 1998-05-28 DE DE69809564T patent/DE69809564T2/de not_active Expired - Lifetime
- 1998-05-28 DK DK98967138T patent/DK1007522T3/da active
- 1998-05-28 AU AU79170/98A patent/AU732722B2/en not_active Ceased
- 1998-05-28 NZ NZ501566A patent/NZ501566A/en unknown
- 1998-05-28 JP JP50144499A patent/JP4344890B2/ja not_active Expired - Fee Related
- 1998-05-28 PL PL337113A patent/PL190777B1/pl unknown
- 1998-05-28 US US09/445,081 patent/US6303608B1/en not_active Expired - Fee Related
- 1998-05-28 RU RU2000100371/04A patent/RU2191184C2/ru not_active IP Right Cessation
- 1998-05-28 EP EP98967138A patent/EP1007522B1/fr not_active Expired - Lifetime
- 1998-05-28 AT AT98967138T patent/ATE228126T1/de not_active IP Right Cessation
- 1998-05-28 CN CN98806845A patent/CN1094491C/zh not_active Expired - Fee Related
- 1998-05-28 CA CA002292746A patent/CA2292746A1/fr not_active Abandoned
- 1998-05-28 BR BR9810240-0A patent/BR9810240A/pt not_active Application Discontinuation
- 1998-05-28 TR TR1999/03001T patent/TR199903001T2/xx unknown
- 1998-05-28 HU HU0002905A patent/HUP0002905A3/hu unknown
- 1998-05-28 PT PT98967138T patent/PT1007522E/pt unknown
- 1998-05-28 IL IL13321698A patent/IL133216A0/xx not_active IP Right Cessation
- 1998-05-29 ES ES009801201A patent/ES2149691B1/es not_active Expired - Fee Related
-
1999
- 1999-12-01 NO NO19995894A patent/NO318757B1/no not_active Application Discontinuation
-
2001
- 2001-03-27 US US09/817,952 patent/US6346620B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6346620B1 (en) | 2002-02-12 |
| NO995894D0 (no) | 1999-12-01 |
| FR2763950A1 (fr) | 1998-12-04 |
| FR2763950B1 (fr) | 2002-09-20 |
| CN1261888A (zh) | 2000-08-02 |
| HUP0002905A2 (hu) | 2001-06-28 |
| PT1007522E (pt) | 2003-04-30 |
| RU2191184C2 (ru) | 2002-10-20 |
| DE69809564T2 (de) | 2003-07-10 |
| ES2149691B1 (es) | 2001-05-16 |
| US6303608B1 (en) | 2001-10-16 |
| TR199903001T2 (xx) | 2000-07-21 |
| NZ501566A (en) | 2001-06-29 |
| HUP0002905A3 (en) | 2002-01-28 |
| DE69809564D1 (de) | 2003-01-02 |
| AU732722B2 (en) | 2001-04-26 |
| WO1998055476A1 (fr) | 1998-12-10 |
| DK1007522T3 (da) | 2003-03-17 |
| KR100556559B1 (ko) | 2006-03-06 |
| JP4344890B2 (ja) | 2009-10-14 |
| EP1007522B1 (fr) | 2002-11-20 |
| KR20010013274A (ko) | 2001-02-26 |
| CA2292746A1 (fr) | 1998-12-10 |
| ATE228126T1 (de) | 2002-12-15 |
| PL337113A1 (en) | 2000-07-31 |
| EP1007522A1 (fr) | 2000-06-14 |
| JP2002501539A (ja) | 2002-01-15 |
| BR9810240A (pt) | 2000-09-05 |
| NO995894L (no) | 2000-02-01 |
| NO318757B1 (no) | 2005-05-02 |
| PL190777B1 (pl) | 2006-01-31 |
| AU7917098A (en) | 1998-12-21 |
| ES2149691A1 (es) | 2000-11-01 |
| CN1094491C (zh) | 2002-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
| NO324230B1 (no) | Anvendelse av 1- [4-(5-cyanindol-3yl)butyl ]-4-(2-karbamoylbenzofuran-5-yl)-piperazin og dets fysiologisk akseptable salter til fremstilling av medikamenter for behandling av bipolare forstyrrelser og mani | |
| GEP20043269B (en) | Purine Derivatives, Method for Their Production and Composition Containing the Same | |
| ATE363282T1 (de) | Zusammensetzung zur unterdrückung von magensäure | |
| MY128659A (en) | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | |
| JO2371B1 (en) | 4-phenyl-pyridine derivatives | |
| ATE348829T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen | |
| HUP0102203A3 (en) | Use of optically pure(+)-norcisapride for producing pharmaceutical compositions suitable for treating apnea, bulimia and other disorders | |
| DE69814394D1 (de) | Verwendung von levobupivacain | |
| MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
| IL133216A0 (en) | 2-ä4-[4(4,5-Dichloro-2-methylimidazol-1-yl) butyl]-1 piperazinylü-5-fluoropyrimidine preparation and therapeutic use | |
| WO2002005801A3 (en) | Compositions containing diacyltartaric salts of (e)-metanicotine | |
| NZ334571A (en) | Pharmaceutical composition comprising 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-acetic acid for treating diseases induced by respiratory syncytial virus | |
| BR0009080A (pt) | Método de tratamento da apnéia do sono | |
| AP2000002017A0 (en) | Salts of paroxetine. | |
| ATE294572T1 (de) | Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten | |
| YU67402A (sh) | Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli | |
| MXPA04001805A (es) | Nueva forma de dosificacion oral de liberacion prolongada. | |
| HUP0401912A3 (en) | Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them | |
| DK1105132T3 (da) | Anvendelse af R(+)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinemethanol til behandling af obstruktiv søvnapnø | |
| MXPA04001812A (es) | Nueva forma de dosificacion oral de liberacion prolongada. | |
| WO1999019324A3 (en) | Antipsychotic substituted piperidine derivatives | |
| SE0102888D0 (sv) | New formulation | |
| MX9706133A (es) | Uso de los derivados de 1-{4-[4-aril(o heteroaril)-1-piperazinil]-butil}-1h-azol para la preparacion de un medicamento destinado al tratamiento de lostrastornos obsesivo-compulsivos, de la apnea del sueño, de las disfunciones sexuales, de la emesis | |
| WO2002036554A3 (en) | Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |